A recent systematic review by Lambertini et al. [81] aimed to assess the efficacy and safety of temporary ovarian suppression using GnRH agonists during chemotherapy in premenopausal women with early breast cancer and found that this therapy appears to be an effective and safe option for premenopausal patients with early breast cancer. This evidence concerns the gene GNRH1 and breast carcinoma.